02.06.2025 • News

BASF to Acquire Shares in Alsachimie

BASF and DOMO Chemicals have signed an agreement giving BASF the right to acquire DOMO Chemicals' 49% stake in the Alsachimie joint venture, in which BASF currently holds 51%.

Aerial view of the Chalampé site
Aerial view of the Chalampé site
© BASF

Under applicable law, the proposed transaction is subject to consultations with the relevant social bodies of Alsachimie, following which both companies would enter into a binding purchase agreement. Subject to these consultations, BASF and DOMO Chemicals expect the transaction to be completed by mid-2025.

For BASF, the 100% acquisition of Alsachimie would be a strategic step to complement the company's strong presence in Chalampé, France, its European center for the production of polyamide (PA) 6.6 precursors. As sole owner of Alsachimie, BASF would be able to further strengthen the production structure and maximize the backward integration of key raw materials in the PA 6.6 value chain.

“As a key supplier for polyamide 6.6 precursors, it is our priority to ensure the reliable supply in Europe,” said Stephan Kothrade, member of the Board of Executive Directors of BASF. “By taking over the shares of our partner DOMO Chemicals, we are further strengthening our leading position and long-term commitment to the polyamide 6.6 value chain and paving the way for future growth with our customers in industries such as automotive and textiles.”

“For DOMO Chemicals, the intended transaction aligns with our strategy to continue to focus on delivering tailored polyamide solutions in the core segments automotive, consumer goods, industrial and electrical & electronics industries,” said Yves Bonte, CEO DOMO Chemicals.

Alsachimie was founded in February 2020 as a joint venture between BASF (51%) and DOMO Chemicals (49%). The company is located at the French-German border and produces essential precursors for polyamides, including KA-oil, adipic acid and hexamethylenediamine adipate (AH salt).

Company

Logo:

BASF SE

Carl-Bosch-Straße 38
67056 Ludwigshafen
Germany

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

most read